Back and forth action as we digest the machinations of the oil market, and some slight weakness mid-day today with news that Gilead's remdesivir flops in first trial. It's interesting to see the broken wedge acting as resistance, but the 20-moving average on the day is acting as support. Still watching to see how this plays out, with a bearish bias.